The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global D-dimer testing market is expected to exhibit a CAGR of 4.45% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
D-dimer testing refers to blood tests used for the diagnosis of deep vein thrombosis (DVT), pulmonary embolism, and disseminated intravascular coagulation (DIC). The tests are conducted to identify the presence of D-dimer in the blood and locate any chronic clots in the body. The tests involve the introduction of monoclonal anti-D-dimer bodies with latex particles that enhance the molecular weight of the immunocomplexes in the test sample. The resulting change in the sample's turbidity is captured photometrically by various turbidimetric analyzers. These tests are usually conducted in hospitals, diagnostic centers, and laboratories.
The increasing prevalence of chronic medical ailments, such as atrial fibrillation, coronary artery disease, and acute pancreatitis, across the globe, is among the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, and the increasing health consciousness among the masses are providing a thrust to the market growth. Various technological advancements, such as the development of next-generation Point-of-Care (PoC) D-dimer testing solutions, are acting as other growth-inducing factors. These innovative solutions process the results faster with enhanced accuracy and minimize the waiting time, resulting in an improved patient experience. Moreover, diagnostic centers are also widely using aptamers that minimize the requirement of antibodies for D-dimer testing and are more cost-effective in nature, thereby creating a positive outlook for market growth. Other factors, including rising healthcare expenditure capacities of the consumers, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global D-dimer testing market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on test type, product, method, application and end use.
Breakup by Test Type:
Breakup by Product:
Breakup by Method:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Unbound Medicine Inc and Werfen.
|Base Year of the Analysis||2021|
|Segment Coverage||Test Type, Product, Method, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott Laboratories, BioMedica Diagnostics, biomérieux SA, Diazyme Laboratories Inc. (General Atomics), F. Hoffmann-La Roche Ltd., HORIBA Ltd., Quidel Corporation, Sekisui Diagnostics LLC (Sekisui Chemical Co. Ltd.), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., Unbound Medicine Inc and Werfen|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at